Paper36074992
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication.
Paul H and 11 others. Blood Adv, 2023. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication. Papers, record 36074992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36074992
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hemophilia A | Major topic |
| Hemostatics | Major topic |
| Humans | |
| Prospective Studies | |
| Factor VIII | |
| Immune Tolerance | |
| Immunoglobulin G |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01652027 | Hemophilia Inhibitor Previously Untreated Patient Study | Derived from the trial | Yes |
Source ClinicalTrials.gov
References83
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12846803 | Extrafollicular antibody responses. | Immunol Rev | 2003 | https://conductscience.org/library/papers/12846803 | PubMed |
| 2 | 21951822 | Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience. | Haemophilia | 2012 | https://conductscience.org/library/papers/21951822 | PubMed |
| 3 | 20536983 | Modulation of factor VIII-specific memory B cells. | Haemophilia | 2010 | https://conductscience.org/library/papers/20536983 | PubMed |
| 4 | 34847225 | Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. | Blood Adv | 2022 | https://conductscience.org/library/papers/34847225 | PubMed |
| 5 | 22260405 | Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. | Eur J Haematol | 2012 | https://conductscience.org/library/papers/22260405 | PubMed |
| 6 | 14872427 | Environmental and genetic factors influencing inhibitor development. | Semin Hematol | 2004 | https://conductscience.org/library/papers/14872427 | PubMed |
| 7 | 11247642 | Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. | J Autoimmun | 2001 | https://conductscience.org/library/papers/11247642 | PubMed |
| 8 | 31447396 | Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. | Transfus Apher Sci | 2019 | https://conductscience.org/library/papers/31447396 | PubMed |
| 9 | 29262350 | CCR6 Defines Memory B Cell Precursors in Mouse and Human Germinal Centers, Revealing Light-Zone Location and Predominant Low Antigen Affinity. | Immunity | 2017 | https://conductscience.org/library/papers/29262350 | PubMed |
| 10 | 17958750 | Factor VIII-specific memory B cells in patients with hemophilia A. | J Thromb Haemost | 2007 | https://conductscience.org/library/papers/17958750 | PubMed |
| 11 | 34337772 | Plasma cell survival: The intrinsic drivers, migratory signals, and extrinsic regulators. | Immunol Rev | 2021 | https://conductscience.org/library/papers/34337772 | PubMed |
| 12 | 33096040 | Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. | Immunity | 2020 | https://conductscience.org/library/papers/33096040 | PubMed |
| 13 | 16091456 | High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. | Blood | 2005 | https://conductscience.org/library/papers/16091456 | PubMed |
| 14 | 30427582 | The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. | Haemophilia | 2019 | https://conductscience.org/library/papers/30427582 | PubMed |
| 15 | 17322888 | FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. | Nat Immunol | 2007 | https://conductscience.org/library/papers/17322888 | PubMed |
| 16 | 32327153 | Unraveling the mysteries of plasma cells. | Adv Immunol | 2020 | https://conductscience.org/library/papers/32327153 | PubMed |
| 17 | 34727394 | Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. | Haemophilia | 2022 | https://conductscience.org/library/papers/34727394 | PubMed |
| 18 | 20546303 | Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. | FEBS J | 2010 | https://conductscience.org/library/papers/20546303 | PubMed |
| 19 | 15148338 | In vivo instruction of suppressor commitment in naive T cells. | J Exp Med | 2004 | https://conductscience.org/library/papers/15148338 | PubMed |
| 20 | 22101900 | The principal results of the International Immune Tolerance Study: a randomized dose comparison. | Blood | 2012 | https://conductscience.org/library/papers/22101900 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42374266 | Immunogenic implications of translational readthrough modulate the association of F8 nonsense mutations with inhibitors in Hemophilia A. | Mol Med | 2026 | https://conductscience.org/library/papers/42374266 | PubMed |
| 42216704 | Nonneutralizing Antibodies in Haemophilia A Patients: To Be Ignored or Not to Be! | Haemophilia | 2026 | https://conductscience.org/library/papers/42216704 | PubMed |
| 39476969 | Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody production. | J Thromb Haemost | 2025 | https://conductscience.org/library/papers/39476969 | PubMed |
| 38455035 | The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A. | Front Immunol | 2024 | https://conductscience.org/library/papers/38455035 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| F8 | 2157 | PubTator's text mining | https://conductscience.org/library/genes/2157 | NCBI Gene |
| FCGR2B | 2213 | PubTator's text mining | https://conductscience.org/library/genes/2213 | NCBI Gene |
| IGHG3 | 3502 | PubTator's text mining | https://conductscience.org/library/genes/3502 | NCBI Gene |
| LOC102723407 | 102723407 | PubTator's text mining | https://conductscience.org/library/genes/102723407 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36074992
GET https://conductscience.org/api/papers/v1/36074992/references?page=2